The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000704392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
22/05/2026
Date registered
Help: Date registered
12/06/2026
Date last updated
Help: Date last updated
12/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase II study of elranatamab in newly diagnosed systemic light-chain (AL) amyloidosis
Scientific title
A Bayesian Phase II study with toxicity monitoring of elranatamab monotherapy in newly diagnosed systemic light-chain (AL) amyloidosis
Additional trial identifiers [1] 316697 0
AMaRC 25-01
Universal Trial Number (UTN)
Trial acronym
ENLIGHT
Related trial records

Health condition
Health condition(s) studied:
Amyloidosis 340944 0
Condition category
Condition code
Blood 337099 337099 0 0
Haematological diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a phase II single arm clinical study.
Elrantamab will be administered by hospital staff and is given subcutaneously. Each treatment cycle is 28 days and maximum number of treatment cycles is 6. Treatment cycles will be back to back. There is no treatment break unless due to side effects.
The dose schedule is:
-Cycle 1 Day 1 - 12mg
-Cycle 1 Day 4 - 32mg
-Cycle 1 Day 8: 76mg
-Cycle 1 Day 15 - 76mg
-Cycle 1 Day 22 - 76mg
-Cycle 2 - 76mg weekly
- From Cycle 3 onwards, dosing frequency will be guided by disease response. If a participant achieves a Complete Response (CR) from the blood tests at Cycle 3 Day 1 or prior, elranatamab will be given every 4 weeks (76mg) till the end of Cycle 6. For participants haven't achieved CR at Cycle 3 Day 1, treatment will be given every 2 weeks (76mg) till reassessed at Cycle 5 Day 1. If participant achieves CR at Cycle 5 Day 1, treatment will be given every 4 weeks (76mg) till the end of Cycle 6. Otherwise, participant will continue with 76mg every 2 weeks till the end of Cycle 6.

Adherence to the intervention will be closely monitored by study staff. Elranatamab is administered subcutaneously by hospital staff at scheduled study visits, ensuring that all doses are given under direct supervision. Administration dates, doses, and any missed, delayed, interrupted, or discontinued treatments will be documented in the participant's study records and case report forms. Compliance with the protocol-specified dosing schedule will be reviewed throughout the study, and any deviations will be recorded and assessed by the study team.
Intervention code [1] 333375 0
Treatment: Drugs
Description of the comparator or control
Single arm study, no control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345005 0
To determine preliminary efficacy of elranatamab in newly diagnosed AL amyloidosis.
Timepoint [1] 345005 0
Achievement of CR at any time within the first 6 cycles. Assessed at end of treatment unless participant comes off treatment earlier. Blood tests will be taken every 2 weeks from cycle 1 to cycle 3, and every 4 weeks from cycle 4 to cycle 6.
Primary outcome [2] 345010 0
To assess the safety of elranatamab in newly diagnosed AL amyloidosis.
Timepoint [2] 345010 0
DLT is assessed during the first cycle (from cycle 1 day 1 to cycle 1 day 28).
Secondary outcome [1] 460107 0
To assess the overall survival
Timepoint [1] 460107 0
Measured from the date of first dose to the date of death
Secondary outcome [2] 460128 0
To assess an estimate of progression free survival
Timepoint [2] 460128 0
Measured from the date of first dose of study drug until the earlier of the date that progressive disease (PD) is first observed or the date of death. Response will be measured day 1 of each cycle during treatment (6 cycles) and every 3 months during follow up until the disease progression. Maximum follow up is 5 years.
Secondary outcome [3] 460132 0
To assess the free light chain (FLC) mass spectrometry (MS) measurable residual disease (MRD) negativity rate
Timepoint [3] 460132 0
Measured at 1, 3, 6, 12, 24, 36, 48 and 60 months till disease progression, whichever comes first.
Secondary outcome [4] 460133 0
To assess haematological Complete Response rates
Timepoint [4] 460133 0
Measured at 2 weeks, 1, 3, 12, 24 months
Secondary outcome [5] 460134 0
To assess organ response rates
Timepoint [5] 460134 0
Measured at 3, 6, 12, 24, 36, 48, and 60 months till disease progression or death, whichever comes first
Secondary outcome [6] 460135 0
To assess change in patient-reported outcomes. This will be assessed as a composite outcome.
Timepoint [6] 460135 0
Measured at day 1 of each cycle during treatment (6 cycles) and every 3 months during follow up until disease progression or death, whichever comes first. Maximum follow up is 5 years.
Secondary outcome [7] 460136 0
To assess the incidence and severity of adverse events (AEs)
Timepoint [7] 460136 0
Participants will be clinically assessed at day 1 of each treatment cycle and at end of treatment
Secondary outcome [8] 460137 0
To assess the major organ deterioration progression-free survival (MOD-PFS)
Timepoint [8] 460137 0
Assessed every 3 months during follow up until disease progression or death, whichever occurs first.

Eligibility
Key inclusion criteria
1.At least 18 years old.
2.Capable of giving consent
3.No contraindication to the use of the study drug and able to comply with trial requirements.
4.Histopathological diagnosis of AL amyloidosis based on detection by polarizing light microscopy of green bi-refringent material in Congo red-stained tissue specimens (in an organ other than bone marrow) or characteristic electron microscopy appearance.
5.Measurable disease of amyloid light chain amyloidosis as defined by at least ONE of the following:
o Serum M-protein at least 5g/L by protein electrophoresis (routine serum protein electrophoresis and immunofixation (IFE) performed at a central laboratory, this cannot be an IgM M-protein),
o Serum free light chain at least 50 mg/L with an abnormal kappa: lambda ratio or the difference between involved and uninvolved free light chains (dFLC) at least 50 mg/ L.
o Note: Measurable disease by urine Bence-Jones proteinuria or IgM M-protein is not sufficient for study enrolment.
6.One or more organs impacted by AL amyloidosis according to consensus guidelines
7.ECOG Performance Status 0-2.
8.Clinical laboratory values meeting the following criteria during the Screening Phase:
o Absolute neutrophil count greater than or equal to 1.0 × 109/L;
o Haemoglobin level greater than or equal to80 g/L; red blood cell transfusion allowed until 7 days before registration.
o Platelet count greater than or equal to75,000/µL if less than 50% of BM nucleated cells are plasma cells, or greater than or equal to 50,000/µL if at least 50% of BM nucleated cells are plasma cells (transfusion support is permitted if completed at least 7 days prior to eligibility sample collection and at least 7 days prior to planned start of dosing)
o Alanine aminotransferase level (ALT) less than or equal to 2.5 times the ULN.
o Aspartate aminotransferase (AST) less than or equal to 2.5 times the ULN.
o Total bilirubin level less than or equal to 1.5 × ULN except for subjects with Gilbert syndrome, in which case direct
bilirubin less than or equal to 2 × ULN.
o Estimated glomerular filtration rate (eGFR) greater than or equal to 20 mL/min/1.73 m2.
9.Women of childbearing potential must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously. Contraception must begin 4 weeks prior to dosing and continue for 4 months after discontinuation of elranatamab. During this same period a woman must agree not to donate eggs for the purposes of assisted reproduction.
10.Woman of childbearing potential must have a negative pregnancy test result within 72 hours of treatment initiation.
11.A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control during and for 4 months after discontinuation of elranatamab. During this same period all men must not donate sperm.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1.Prior therapy for AL amyloidosis or multiple myeloma, except for 160 mg dexamethasone (or equivalent corticosteroid) maximum exposure prior to treatment initiation.
2.Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, anaemia, greater than or equal to 60% plasma cells in the bone marrow or hypercalcemia. IF the only myeloma defining feature is an involved-to-uninvolved free light chain ratio greater than or equal to 100:1, that is permitted.
3. Patients with AL amyloidosis associated with a clonal lymphoplasmacytic or B-cell population.
4. Evidence of significant cardiovascular conditions.
5.Planned stem cell collection or stem cell transplant during the first 6-months of therapy
6. Any form of non-AL amyloidosis, including wild type or mutated (ATTR) amyloidosis.
7. Known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients, or known sensitivity to mammalian-derived products.
8. Chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) 2 years.
o Stage 1 prostate cancer that does not require treatment.
o Any other cancer from which the subject has been disease-free for > 2 years.
13. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
14.Participation in other clinical trials for the treatment of AL amyloidosis, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 29384 0
The Alfred - Melbourne
Recruitment hospital [2] 29385 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment hospital [3] 29386 0
Box Hill Hospital - Box Hill
Recruitment hospital [4] 29387 0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Recruitment postcode(s) [1] 45703 0
3004 - Melbourne
Recruitment postcode(s) [2] 45704 0
3065 - Fitzroy
Recruitment postcode(s) [3] 45705 0
3128 - Box Hill
Recruitment postcode(s) [4] 45706 0
2010 - Darlinghurst

Funding & Sponsors
Funding source category [1] 321302 0
Other Collaborative groups
Name [1] 321302 0
Australasian Myeloma Research Consortium
Country [1] 321302 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australasian Myeloma Research Consortium
Address
Country
Australia
Secondary sponsor category [1] 324030 0
None
Name [1] 324030 0
Address [1] 324030 0
Country [1] 324030 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319834 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 319834 0
Ethics committee country [1] 319834 0
Australia
Date submitted for ethics approval [1] 319834 0
20/02/2026
Approval date [1] 319834 0
15/05/2026
Ethics approval number [1] 319834 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148558 0
Prof Hang Quach
Address 148558 0
St Vincent’s Hospital Melbourne, 41 Victoria Pde, Fitzory, VIC 3065
Country 148558 0
Australia
Phone 148558 0
+61 3 9231 3189
Fax 148558 0
Email 148558 0
Contact person for public queries
Name 148559 0
Khoa Le
Address 148559 0
Level 2, South Block, Alfred Hospital, 55 Commercial Road, Melbourne VIC 3004
Country 148559 0
Australia
Phone 148559 0
+61 3 9076 7851
Fax 148559 0
Email 148559 0
Contact person for scientific queries
Name 148560 0
Hang Quach
Address 148560 0
St Vincent’s Hospital Melbourne, 41 Victoria Pde, Fitzory, VIC 3065
Country 148560 0
Australia
Phone 148560 0
+61 3 9231 3189
Fax 148560 0
Email 148560 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.